-
2024-513912-89-00
10
2018-12-13
Primary Or Secondary (Post-PV MF or Post-ET-MF) Myelofibrosis (MF) Wit
-
2023-510009-16-00
9
2018-12-04
Acute Myeloid Leukemia
-
2022-501817-29-00
5
2018-11-27
High Risk Non-muscle invasive bladder cancer
-
2023-505376-30-00
4
2018-10-30
BRAF V600 mutation–positive unresectable or metastatic melanoma
-
2023-510517-26-00
9
2018-10-26
Acute Myeloid Leukemia
-
2023-506112-40-00
5
2018-09-26
R/R Multiple Myeloma
-
2024-512049-17-00
6
2018-09-05
Newly diagnosed MM patients >= 65 years old or ineligible for autologo
-
2023-508018-41-00
4
2018-07-27
Primary Myelofibrosis (PMF), Post-polycythemia Vera or Post-essential
-
2023-509856-32-00
5
2018-07-15
acute lymphoblastic leukemia in children and adolescents
-
2023-509976-40-00
5
2018-05-28
Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
-
2024-513070-21-00
4
2018-02-15
Relapsed Acute Lymphoblastic Leukemia (ALL)
-
2024-514309-73-00
5
2018-02-06
Previously Untreated Acute Myeloid Leukemia with an IDH1 Mutation
-
2024-514417-34-00
5
2017-12-14
Cancer
-
2024-510840-30-00
4
2017-12-01
Hormone Naive Prostate Cancer
-
2024-515499-12-00
5
2017-10-02
Acute lymphoblastic leukemia
-
2023-506415-18-00
9
2017-07-18
Hodgkin lymphoma (HL) - Hodgkin lymphoma (HL), a neoplasm of lymphoid
-
2023-509354-58-00
5
2017-07-14
Mantle Cell Lymphoma
-
2023-509671-17-00
5
2017-07-12
Breast Cancer
-
2024-514686-19-00
4
2017-03-10
Relapsed or Refractory Chronic Lymphocytic Leukemia
-
2023-510434-83-00
6
2016-10-17
Chronic Myeloid Leukemia (CML) in Chronic Phase (CP)
-
2023-504311-32-00
9
2016-09-02
Chronic Myeloid Leukemia
-
2024-515749-40-00
5
2016-02-25
Malignant melanoma of the skin in patients with locally advanced and f
-
2023-505981-26-00
5
2015-11-20
Non−Small Cell Lung Cancer
-
2024-513654-30-00
4
2015-11-04
Diffuse intrinsic pontine glioma